When a new pathogen invades, it’s a race against time for your immune system to stop it from multiplying out of control. This week, we explore Protein Based Vaccines as part of our “How Does It Work?” series. Fortunately, #vaccines give your immune system a head start against dangerous pathogens. A protein-based vaccine, like this …Read More >

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

WuXi AppTec offers comprehensive structural generation solutions for today´s challenging targets. Our experts provide insights and data to support hit finding through to lead optimization.

WuXi AppTec  | Target-to-Hit Solutions Protein Production  | All Target Classes and Challenging Proteins Biophysical & Biochemical Platforms |  Ready-To-Go Assay for Broad Range of Drug Targets Structural Biology Platforms Covalent and non-covalent fragment libraries & Screening